Form 4: Dyne Therapeutics Director Dirk Kersten Reports Stock Sales

Director Dirk Kersten reports sales of Dyne Therapeutics (DYN) stock through a Rule 10b5-1 trading plan.

Summary

• Dirk Kersten, a director of Dyne Therapeutics, reported the sale of common stock on August 20 and 21, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (FCF IV) on April 9, 2024.
• On August 20, 2024, shares were sold in multiple transactions at weighted average prices of $45.68, $46.94, and $47.3.
• On August 21, 2024, shares were sold in multiple transactions at weighted average prices of $46.52 and $47.01.
• The reported transactions decreased the number of shares held directly by FCF IV and ForDyne B.V. (ForDyne), entities over which Kersten may have voting and dispositive power.
• Kersten disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock sales by a director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider trading activity. The use of a 10b5-1 plan suggests pre-planned sales, reducing potential negative interpretations.

Industry Context

This Form 4 filing is a routine disclosure of stock transactions by a company insider. It provides transparency to the market regarding the trading activities of individuals with access to non-public information.

Stakeholder Impact

• The stock sales could potentially influence investor sentiment, although the use of a pre-arranged trading plan may mitigate concerns about insider information.

Key Dates